Back to Authors

Huang, Haojie

https://orcid.org/0000-0002-3100-5301

Mayo Clinic

Changhai Hospital

Citations 5

Plasma Extracellular Vesicle Proteomics Reflects Graded Inflammation within the COCA Classification Framework for Chronic Pancreatitis
Wang, Heru, Zhang, Di , Li, Jiayu, Huang, Haojie, Ji, Baoan , Wang, Lixiang , Huang, Haojie

Pancreas | May 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mpa.0000000000002675 Get It

Structural insight into the CUB2 domain’s role in enteropeptidase-mediated trypsinogen activation
Song, Qiuyue, Peng, Lisi , Yang, Xia , Xu, Jiaheng , Zhang, Deyu , Tian, Xiaorong, Li, Shiyu , Ji, Baoan , Jin, Zhendong, Ding, Zhanyu , Li, Zhaoshen , Huang, Haojie, Huang, Haojie , Song, Qiuyue , Li, Shiyu, Zhang, Yu , Li, Zhaoshen , Huang, Haojie

Proceedings of the National Academy of Sciences | March 16, 2026 | Volume: 123 | Issue: 12 | Pages: No page available

10.1073/pnas.2521394123 Get It

Elucidating the structure and function of enteropeptidase (EP) is essential for advancing our understanding of its biological significance, particularly in regulating trypsinogen activation. Using cryo-EM and enzymatic activity, we uncovered the significance of the CUB2 domain in mediating the cleavage of macromolecular substrates. We identified crucial binding loops and key residues for EP’s proteolytic function. The mutation E574A enhanced the proteolytic activity of EP, whereas the mutation N619A diminished its cleavage efficiency, highlighting the importance of surface-charged interactions in modulating EP’s activity. A proteolytic cycle was proposed to deepen our understanding of the trypsinogen activation by EP. This work offers valuable insights into the molecular mechanisms underlying EP’s interaction with its substrate, and opens up avenues for therapeutically modulating EP-mediated proteolysis.
Unraveling the Microenvironment and the Pathogenic Axis of HIF‐1α–Visfatin–Fibrosis in Autoimmune Pancreatitis Using a Single‐Cell Atlas
Zhang, Deyu , Ma, Congjia , Liu, Yanfang , Liu, Zaoqu, Li, Wanshun , Liu, Yue , Wu, Chang , Sun, Liqi , Jiang, Fei , Jiang, Hui , Su, Xiaoju, Peng, Lisi , Wang, Xinyue , Yin, Hua, Wan, Dongling, Zhou, Yuyan , Tian, Xiaorong , Li, Shiyu , Jin, Zhendong , Ji, Baoan , Li, Zhaoshen , Huang, Haojie , Wang, Zhen , Huang, Haojie , Wang, Zhen , Li, Jiayu , Li, Zhaoshen

Advanced Science | January 31, 2025 | Volume: 12 | Issue: 12 | Pages: No page available

10.1002/advs.202412282 Get It

AbstractAutoimmune pancreatitis (AIP) is identified as a severe chronic immune‐related disorder in pancreas, including two subtypes. In this study, pancreatic lesions in patients diagnosed as either type 1 AIP or type 2 AIP are examined, and these patients’ peripheral blood at single‐cell level. Furthermore, flow cytometry, immunofluorescence, and functional assays are performed to verify the identified cell subtypes. In type 1 AIP, there is a notable increase in the amount of B cells and plasma cells, and IgG4+ plasma cells are key pathogenic cells of AIP. The differentiation path of naïve‐stage B cells into IgG4+ produced plasma cells is observed, and an increased amount of T helper cells and T follicular helper (Tfh) cells. This study also reveals that HIF‐1α, an activated transcriptional factor, can directly bind to promoter site of NAMPT, promoting higher levels of visfatin production in HIF1A+ classical monocytes. Pancreatic stellate cells can be activated by extracellular visfatin and promote the development of fibrotic response in pancreatic lesions across both AIP subtypes. The current findings shed light on the exploration of dynamic alterations in peripheral blood cells and cell subgroups in pancreatic lesions of AIP, while elucidating a pathogenic cell subset and potential fibrosis mechanism of AIP.
STAGER checklist: Standardized testing and assessment guidelines for evaluating generative artificial intelligence reliability
Chen, Jinghong , Zhu, Lingxuan , Zeng, Dongqiang , Qi, Chang , Tang, Bufu , Shi, Wenjie , Guo, Shipeng, Sun, Xu , Ngo, Trunghieu, Pu, Zhongji , He, Yongbin, Wu, Haiyang , Cheungpasitporn, Wisit, Huang, Haojie , Wang, Shixiang , Cabannes, Loïc, Ren, Gerald Sng Gui , Ali, Stephen R , Cheng, Quan, Miao, Kai , Mou, Weiming , Lin, Anqi , Zeng, Dongqiang, Liu, Zaoqu , Jiang, Aimin , Shi, Wenjie, Kahlert, Ulf D. , Zhou, Jian‐Guo , Lu, Xiaofan , Jia, Baolei , Jeon, Che Ok , Gu, Shuqin , Cheungpasitporn, Wisit , Mao, Weipu , Chen, Xin , Cabannes, Loïc, Whitaker, Iain Stuart , Cheng, Quan, Yuan, Shuofeng , Luo, Peng

iMetaOmics | July 2, 2024 | Volume: 1 | Issue: 1 | Pages: No page available

10.1002/imo2.7 Get It

Abstract Generative artificial intelligence (AI) holds immense potential for medical applications, but the lack of a comprehensive evaluation framework and methodological deficiencies in existing studies hinder its effective implementation. Standardized assessment guidelines are crucial for ensuring reliable and consistent evaluation of generative AI in healthcare. Our objective is to develop robust, standardized guidelines tailored for evaluating generative AI performance in medical contexts. Through a rigorous literature review utilizing the Web of Sciences, Cochrane Library, PubMed, and Google Scholar, we focused on research testing generative AI capabilities in medicine. Our multidisciplinary team of experts conducted discussion sessions to develop a comprehensive 32‐item checklist. This checklist encompasses critical evaluation aspects of generative AI in medical applications, addressing key dimensions such as question collection, querying methodologies, and assessment techniques. The checklist and its broader assessment framework provide a holistic evaluation of AI systems, delineating a clear pathway from question gathering to result assessment. It guides researchers through potential challenges and pitfalls, enhancing research quality and reporting and aiding the evolution of generative AI in medicine and life sciences. Our framework furnishes a standardized, systematic approach for testing generative AI's applicability in medicine. For a concise checklist, please refer to Table S or visit GenAIMed.org .
Transgenic expression of cyclooxygenase-2 in pancreatic acinar cells induces chronic pancreatitis
Huang, Haojie , Chen, Jiaxiang , Peng, Lisi , Yao, Yao , Deng, Defeng , Liu, Yan , Li, Zhao‐Shen , Bi, Yan , Haddock, Ashley , Zhan, Xianbao , Logsdon, Craig D. , Ji, Baoan , Haddock, Ashley N, Zhang, Yang , Wang, Huamin , Zhan, Xianbao , Lu, Weiqin

American Journal of Physiology-Gastrointestinal and Liver Physiology | November 15, 2018 | Volume: 316 | Issue: 1 | Pages: G179-G186

10.1152/ajpgi.00096.2018 Get It

Replacement of the exocrine parenchyma by fibrous tissue is a main characteristic of chronic pancreatitis. Understanding the mechanisms of pancreatic fibrogenesis is critical for the development of preventive and therapeutic interventions. Cyclooxygenase-2 (COX-2), a rate-limiting enzyme for prostaglandin synthesis, is expressed in patients with chronic pancreatitis. However, it is unknown whether COX-2 can cause chronic pancreatitis. To investigate the roles of pancreatic acinar COX-2 in fibrogenesis and the development of chronic pancreatitis, COX-2 was ectopically expressed specifically in pancreatic acinar cells in transgenic mice. Histopathological changes and expression levels of several profibrogenic factors related to chronic pancreatitis were evaluated. COX-2 was expressed in the pancreas of the transgenic mice, as detected by Western blot analysis. Immunohistochemical staining showed COX-2 was specifically expressed in pancreatic acinar cells. COX-2 expression led to progressive changes in the pancreas, including pancreas megaly, persistent inflammation, collagen deposition, and acinar-to-ductal metaplasia. Quantitative RT-PCR and immunostaining showed that profibrogenic factors were upregulated and pancreatic stellate cells were activated in the COX-2 transgenic mice. Expression of COX-2 in pancreatic acinar cells is sufficient to induce chronic pancreatitis. Targeting this pathway may be valuable in the prevention of chronic pancreatitis. NEW & NOTEWORTHY COX-2 expression is observed in pancreatic tissues of human chronic pancreatitis. In this study, we showed that COX-2 expression caused the development of chronic pancreatitis in transgenic mice, supporting the idea that COX-2 inhibition may be an effective preventive and therapeutic strategy.